PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsZonisamide
Zonegran(zonisamide)
Zonegran, Zonisade, Zonisamide (zonisamide) is a small molecule pharmaceutical. Zonisamide was first approved as Zonegran on 2000-03-27. It is used to treat epilepsy and partial epilepsies in the USA. It has been approved in Europe to treat epilepsy and partial epilepsies. It is known to target carbonic anhydrase 7, carbonic anhydrase 12, and carbonic anhydrase 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
Trade Name
FDA
EMA
Zonegran, Zonisade (generic drugs available since 2005-12-22)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Zonisamide
Tradename
Company
Number
Date
Products
ZONISADEAzurityN-214273 RX2022-07-15
1 products, RLD, RS
ZONEGRANConcordia LaboratoriesN-020789 RX2000-03-27
2 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
epilepsyEFO_0000474D004827G40.9
partial epilepsiesEFO_0004263D004828—
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Zonisamide, Zonisade, Azurity
114784562038-08-18U-3458
115293332038-08-18DP
ATC Codes
N: Nervous system drugs
— N03: Antiepileptics
— N03A: Antiepileptics
— N03AX: Other antiepileptics in atc
— N03AX15: Zonisamide
HCPCS
No data
Clinical
Clinical Trials
84 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
EpilepsyD004827EFO_0000474G40.91—612726
AlcoholismD000437EFO_0003829F10.1—631111
ObesityD009765EFO_0001073E66.9—31116
SeizuresD012640HP_0002069G40.4——2114
Parkinson diseaseD010300EFO_0002508G20—11113
Migraine disordersD008881EFO_0003821G43—1—113
Partial epilepsiesD004828EFO_0004263————2—2
Intellectual disabilityD008607EFO_0003847F73———112
Bipolar disorderD001714EFO_0000289F30.9—1—1—2
Parkinsonian disordersD020734HP_0001300G20.C———1—1
Show 2 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SchizophreniaD012559EFO_0000692F20—11——2
Psychotic disordersD011618—F20.81—11——2
Smoking cessationD016540EFO_0004319———2——2
Tuberous sclerosisD014402HP_0009720Q85.1——1——1
Weight gainD015430HP_0004324———1——1
Complex partial epilepsyD017029EFO_1000877———1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Noise-induced hearing lossD006317EFO_1001254—13———3
Central nervous system neoplasmsD016543——12———2
Obstructive sleep apneaD020181EFO_0003918G47.33—2———2
Sleep apnea syndromesD012891HP_0010535G47.3—2———2
Post-traumatic stress disordersD013313EFO_0001358F43.1—2———2
Essential tremorD020329EFO_0003108G25.0—1——12
Tobacco use disorderD014029—F1711———1
HypertensionD006973EFO_0000537I10—1———1
Blood pressureD001794EFO_0004325——1———1
Cocaine-related disordersD019970—F1411———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———6————6
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Developmental disabilitiesD002658EFO_0003852F89————11
CraniotomyD003399——————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameZonisamide
INNzonisamide
Description
Zonisamide is a 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position. It has a role as an anticonvulsant, an antioxidant, a central nervous system drug, a protective agent and a T-type calcium channel blocker. It is a member of 1,2-benzoxazoles and a sulfonamide.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
NS(=O)(=O)Cc1noc2ccccc12
Identifiers
PDB—
CAS-ID68291-97-4
RxCUI—
ChEMBL IDCHEMBL750
ChEBI ID10127
PubChem CID5734
DrugBankDB00909
UNII ID459384H98V (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
CA7
CA7
CA12
CA12
CA1
CA1
Organism
Homo sapiens
Gene name
CA7
Gene synonyms
NCBI Gene ID
766
Protein name
carbonic anhydrase 7
Protein synonyms
CA-VII, Carbonate dehydratase VII, Carbonic anhydrase VII, carbonic dehydratase VII
Uniprot ID
P43166
Mouse ortholog
Car7 (12354)
carbonic anhydrase 7 (Q9ERQ8)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Zonisamide
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 4,467 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
5,568 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use